CLYM Q1 2024 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena

CLYMClimb Bio, Inc.

$522M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$3M

Net Income

-$2M

EPS (Diluted)

$-0.06

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$465,000

Balance Sheet

Total Assets

$109M

Total Liabilities

$3M

Stockholders' Equity

$106M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$3M	-$23M	+87.2%
Net Income	-$2M	-$22M	+92.4%